Ankur Dhingra
Ankur Dhingra's purchase track record
How the stock did after each of Ankur Dhingra's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2025 | ILMN | $495K | +16.2% | +49.2% | +16.9% |
| 3/26/2024 | SMMT | $375K | +114.2% | +541.7% | +10.2% |
| 12/13/2023 | SMMT | $44K | +92.7% | +252.6% | +15.2% |
| 3/7/2023 | SMMT | $206K | +43.5% | +13.8% | +12.8% |
| 8/16/2022 | SMMT | $35K | +7.9% | +105.9% | -3.9% |
| 11/24/2021 | CDNA | $212K | -19.2% | -45.8% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
CareDx shows high growth and fair‑value boost after reimbursement news. Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.
Transaction History
| ILMN | ▲ Buy | Grant | 9,358 | $1.2M | 3/5/2026 | View on chart |
| ILMN | ▲ Buy | Open Market | 6,100 | $495K | 5/12/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 9,803 | $0 | 3/5/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 8,826 | $0 | 5/6/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 100,000 | $375K | 3/26/2024 | View on chart |
| SMMT | ▲ Buy | Open Market | 700 | $2K | 12/13/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 19,700 | $43K | 12/13/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 196,362 | $206K | 3/7/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 24,658 | $24K | 8/16/2022 | View on chart |
| SMMT | ▲ Buy | Open Market | 11,557 | $11K | 8/16/2022 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,254 | $48K | 3/25/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 19,900 | $0 | 2/2/2022 | View on chart |
| CDNA | ▲ Buy | Open Market | 5,000 | $212K | 11/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.